BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Opinion

  As Duchenne innovation booms, let’s ensure it becomes real progress

  At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne muscular dystrophy.

  April 21, 2026

   · 

  7 min read

   · 

  Louise Rodino-Klapac
• 

  Lung cancer

  Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls

  The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in lung cancer.

  April 21, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cancer

  AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data

  Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses at head and neck cancer.

  April 21, 2026

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Kidney cancer

  Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer

  A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.

  April 21, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoffs

  Replimune cuts will leave over 200 jobless in Massachusetts

  Replimune is axing 144 employees at its Woburn headquarters and 80 at its Framingham manufacturing site. The cuts follow the FDA’s second rejection of the biotech’s advanced melanoma candidate.

  April 21, 2026

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Series A

  Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs

  With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.

  April 21, 2026

   · 

  1 min read

   · 

  Gabrielle Masson
• Press Releases

  Lirum Therapeutics Announces Positive LX-101 Data Selected for Presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting

  April 21, 2026

   · 

  5 min read
• Press Releases

  Verismo Therapeutics’ Initial Clinical Data from STAR-101 Phase 1 Trial of SynKIR™-110 KIR-CAR Presented at AACR 2026 Plenary Session

  April 21, 2026

   · 

  6 min read
• Press Releases

  AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients

  April 21, 2026

   · 

  9 min read
• Press Releases

  Entos Pharmaceuticals and the L-CMD Research Foundation Collaborate to Develop Curative Therapy for LMNA-Related Congenital Muscular Dystrophy

  April 21, 2026

   · 

  3 min read